Storek Benjamin, Harder Nina M, Banck Michaela S, Wang Cheng, McCarty Douglas M, Janssen William Gm, Morrison John H, Walsh Christopher E, Beutler Andreas S
Department of Medicine (Hematology/Oncology), Mount Sinai School of Medicine, New York, NY, USA.
Mol Pain. 2006 Jan 30;2:4. doi: 10.1186/1744-8069-2-4.
Intrathecal (IT) gene transfer is an attractive approach for targeting spinal mechanisms of nociception but the duration of gene expression achieved by reported methods is short (up to two weeks) impairing their utility in the chronic pain setting. The overall goal of this study was to develop IT gene transfer yielding true long-term transgene expression defined as > or = 3 mo following a single vector administration. We defined "IT" administration as atraumatic injection into the lumbar cerebrospinal fluid (CSF) modeling a lumbar puncture. Our studies focused on recombinant adeno-associated virus (rAAV), one of the most promising vector types for clinical use.
Conventional single stranded rAAV2 vectors performed poorly after IT delivery in rats. Pseudotyping of rAAV with capsids of serotypes 1, 3, and 5 was tested alone or in combination with a modification of the inverted terminal repeat. The former alters vector tropism and the latter allows packaging of self-complementary rAAV (sc-rAAV) vectors. Combining both types of modification led to the identification of sc-rAAV2/l as a vector that performed superiorly in the IT space. IT delivery of 3 x 10e9 sc-rAAV2/l particles per animal led to stable expression of enhanced green fluorescent protein (EGFP) for > or = 3 mo detectable by Western blotting, quantitative PCR, and in a blinded study by confocal microscopy. Expression was strongest in the cauda equina and the lower sections of the spinal cord and only minimal in the forebrain. Microscopic examination of the SC fixed in situ with intact nerve roots and meninges revealed strong EGFP fluorescence in the nerve roots.
sc-rAAVl mediates stable IT transgene expression for > or = 3 mo. Our findings support the underlying hypothesis that IT target cells for gene transfer lack the machinery for efficient conversion of the single-stranded rAAV genome into double-stranded DNA and favor uptake of serotype 1 vectors over 2. Experiments presented here will provide a rational basis for utilizing IT rAAV gene transfer in basic and translational studies on chronic pain.
鞘内(IT)基因转移是一种针对伤害性感受脊髓机制的有吸引力的方法,但报道方法所实现的基因表达持续时间较短(最长两周),这削弱了它们在慢性疼痛环境中的效用。本研究的总体目标是开发一种IT基因转移方法,在单次载体给药后产生定义为≥3个月的真正长期转基因表达。我们将“IT”给药定义为模拟腰椎穿刺的无创性注射入腰椎脑脊液(CSF)。我们的研究聚焦于重组腺相关病毒(rAAV),这是临床应用中最有前景的载体类型之一。
常规单链rAAV2载体在大鼠IT给药后表现不佳。测试了用血清型1、3和5的衣壳对rAAV进行假型化,单独或与反向末端重复序列的修饰相结合。前者改变载体嗜性,后者允许包装自我互补rAAV(sc-rAAV)载体。两种修饰类型的结合导致鉴定出sc-rAAV2/1作为在IT空间中表现优异的载体。每只动物IT注射3×10⁹个sc-rAAV2/1颗粒导致增强型绿色荧光蛋白(EGFP)稳定表达≥3个月,通过蛋白质免疫印迹、定量PCR以及在一项盲法研究中通过共聚焦显微镜均可检测到。表达在马尾和脊髓下段最强,在前脑仅为微量。对固定原位且神经根和脑膜完整的脊髓进行显微镜检查显示神经根中有强烈的EGFP荧光。
sc-rAAV1介导稳定的IT转基因表达≥3个月。我们的发现支持以下潜在假设,即IT基因转移的靶细胞缺乏将单链rAAV基因组有效转化为双链DNA的机制,并且相比于血清型2载体更倾向于摄取血清型1载体。此处呈现的实验将为在慢性疼痛的基础和转化研究中利用IT rAAV基因转移提供合理依据